Quantcast

Latest Roche Stories

2010-07-26 08:00:00

NUTLEY, N.J., July 26 /PRNewswire/ -- Roche announced today that Karen Lackey has been named Vice President and Head of Medicinal Chemistry, effective immediately. In her role at the company's Nutley facility, Karen will be responsible for small molecule drug discovery in oncology, virology and inflammation. She will also oversee the Nutley Discovery Chemistry Management Team and be a member of the Global Chemistry Leadership Team. Karen will report to Hans-Joachim Boehm, Ph.D., Global Head...

48a1727f8de003247378c30a59ea9b72
2010-07-17 06:40:57

Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives. The Food and Drug Administration approved Roche's blockbuster Avastin in 2008 based on early-stage trials after it was seen that it shrank tumors caused by breast cancer.  The decision was controversial because drugs for cancer patients who have never been treated before must show evidence that they extend lives. Avastin's so-called...

2010-07-13 13:12:00

IPSWICH, Mass., July 13 /PRNewswire/ -- New England Biolabs (NEB) has expanded its line of reagents for sample preparation with the introduction of NEBNext(TM) Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium(TM) and GS Junior(TM) instruments. These new products provide all the necessary enzymes and buffers for fast fragment library preparation. The Master Mix Set further streamlines the workflow, reducing the...

2010-07-01 09:00:00

WALTHAM, Mass., July 1 /PRNewswire/ -- X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets. As part of the agreement, Roche will provide X-Chem with upfront and research payments, success-based discovery milestones, and technology access fees. Roche will have the right to develop and commercialise any product...

2010-06-30 23:01:00

YORKTOWN HEIGHTS, N.Y. and BRANFORD, Conn., July 1 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced today an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's...

2010-06-16 08:00:00

NUTLEY, N.J., June 16 /PRNewswire/ -- Armed with a clear focus on helping orphaned children locally as well as thousands of miles away, more than 900 local Roche employees are participating today in the Seventh Annual Roche Children's Walk to raise funds to support children infected and affected by HIV/AIDS in New Jersey and Africa. Employees who volunteer for the 5K Walk, which takes them through the township of Nutley, collect donations and Roche matches the funds. Roche has raised...

2010-06-09 05:51:00

PRINCETON, N.J., June 9, /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care (SOC), was similar to the safety profile of...

2010-06-01 09:01:00

INDIANAPOLIS, June 1 /PRNewswire/ -- Roche, makers of ACCU-CHEK® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C. The "Chancellor's Award" recognizes and honors longstanding JDRF corporate partners. During the presentation, JDRF highlighted Roche's "Bag of Hope" program...

2010-05-17 00:29:00

LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ -- - Trial to Study Patients with Colorectal and Ovarian Cancer ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and...

2010-05-07 06:29:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the first quarter ended March 31, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO) "Halozyme continues to execute its strategy of leveraging our unique technology and...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'